肉腫治療薬の世界市場レポート 2025年

肉腫治療薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.9％で21億8,000万米ドルに成長します。予測期間の成長は、新規治療への需要、ヘルスケア投資、精密医療、臨床試験と発見、研究開発に起因します。予測期間の主な動向には、免疫療法の進歩、併用療法、早期診断イニシアチブ、バイオマーカー研究、患者中心のアプローチなどがあります。

軟部肉腫の罹患率の上昇が肉腫治療薬市場の成長を牽引すると予想されます。軟部肉腫は、筋肉、脂肪、腱、リンパ、神経などの体の軟部組織に発生するがんの一種であり、ヘルスケア業界では肉腫治療薬が効果的に対処しています。これらの薬剤は、がん細胞を標的とし、その増殖を阻害することにより、骨肉腫および軟部肉腫の治療において重要な役割を果たしています。米国がん協会が2023年1月に報告したように、米国では約13,400例の軟部肉腫が新たに診断され、同年に5,140例が死亡すると推定されています。その結果、軟部肉腫の有病率の増加が肉腫治療薬市場の成長を促進する重要な要因となっています。

化学療法に対する需要の高まりは、肉腫治療薬市場の拡大に寄与する見通しです。化学療法は、急速に分裂するがん細胞を死滅させたり、増殖を抑制するために薬剤を使用する医療介入であり、肉腫の治療に幅広く応用されています。化学療法で使用される肉腫治療薬は、腫瘍縮小、補助療法、転移抑制、併用療法、緩和ケア、再発リスク低減、生存率向上など、多様な役割を担っています。2022年2月にヘルスケアITニュースが発表したレポートでは、国際がん対策連合（UICC）を引用して、がん化学療法の需要が2040年までに1,000万人から1,500万人に増加すると予測しています。このような需要の急増は、化学療法への依存の高まりを裏付けるものであり、肉腫治療薬市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の肉腫治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の肉腫治療薬市場：成長率分析
• 世界の肉腫治療薬市場の実績：規模と成長, 2019-2024
• 世界の肉腫治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の肉腫治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の肉腫治療薬市場：治療タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 標的療法
• 世界の肉腫治療薬市場：疾患適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 悪性骨腫瘍
• 軟部肉腫
• 世界の肉腫治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の肉腫治療薬市場、タイプ別サブセグメンテーション：化学療法、実績と予測, 2019-2024, 2024-2029F, 2034F
• アントラサイクリン
• アルキル化剤
• 代謝拮抗物質
• その他の化学療法剤
• 世界の肉腫治療薬市場、タイプ別サブセグメンテーション：標的療法、実績と予測, 2019-2024, 2024-2029F, 2034F
• チロシンキナーゼ阻害剤
• MTOR阻害剤
• モノクローナル抗体
• その他の標的療法

第7章 地域別・国別分析

• 世界の肉腫治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の肉腫治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肉腫治療薬市場：競合情勢
• 肉腫治療薬市場：企業プロファイル
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services Inc.
• Novartis AG
• Pfizer Inc.
• AgonOX Inc.
• Daiichi Sankyo Company Limited
• Merck & Co. Inc.
• AbbVie Inc.
• Amneal Pharmaceuticals LLC
• Pharma Mar SA
• Bristol-Myers Squibb Company
• Fresenius Kabi AG
• Ipsen SA
• Radiopharm Theranostics
• Akeso Biopharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 肉腫治療薬市場2029：新たな機会を提供する国
• 肉腫治療薬市場2029：新たな機会を提供するセグメント
• 肉腫治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Sarcoma drugs are pharmaceuticals designed for the treatment of sarcoma, a type of cancer that originates in connective tissues such as fat, muscle, blood vessels, nerves, and bones. These drugs are specifically formulated to target abnormal cells, either by directly inducing their death or by inhibiting their growth and multiplication.

The primary treatment modalities for sarcoma drugs include chemotherapy and targeted therapy. Chemotherapy, a widely employed cancer treatment, utilizes drugs to combat cancer cells. The range of disease indications for sarcoma drugs encompasses malignant bone tumors and soft tissue sarcoma, with distribution facilitated through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and other relevant outlets.

The sarcoma drugs market research report is one of a series of new reports from The Business Research Company that provides sarcoma drugs market statistics, including sarcoma drugs industry global market size, regional shares, competitors with a sarcoma drugs market share, detailed sarcoma drugs market segments, market trends and opportunities, and any further data you may need to thrive in the sarcoma drugs industry. This sarcoma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sarcoma drugs market size has grown strongly in recent years. It will grow from$1.37 billion in 2024 to $1.49 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to healthcare infrastructure, treatment guidelines, patient advocacy groups, improved diagnosis methods, increased disease awareness

The sarcoma drugs market size is expected to see strong growth in the next few years. It will grow to $2.18 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to demand for novel therapies, healthcare investment, precision medicine, clinical trials and discoveries, research and development. Major trends in the forecast period include immunotherapy advancements, combination therapies, early diagnosis initiatives, biomarker research, patient-centric approach.

The escalating incidence of soft tissue sarcoma is expected to drive the growth of the sarcoma drugs market. Soft tissue sarcoma, a form of cancer originating in the body's soft tissues such as muscles, fat, tendons, lymph, and nerves, is effectively addressed by sarcoma drugs in the healthcare industry. These drugs play a crucial role in treating both bone and soft tissue sarcoma by targeting and disrupting the growth of cancer cells. As reported by the American Cancer Society in January 2023, approximately 13,400 new cases of soft tissue sarcomas are anticipated to be diagnosed in the United States, with an estimated 5,140 deaths attributed to this form of cancer in the same year. Consequently, the increasing prevalence of soft tissue sarcoma is a significant factor propelling the growth of the sarcoma drugs market.

The growing demand for chemotherapy is poised to contribute to the expansion of the sarcoma drugs market. Chemotherapy, a medical intervention involving the use of drugs to kill or inhibit the growth of rapidly dividing cancer cells, finds extensive application in the treatment of sarcoma. Sarcoma drugs utilized in chemotherapy play diverse roles, including tumor reduction, adjuvant treatment, metastasis control, combination therapy, palliative care, risk reduction of recurrence, and enhancement of survival rates. A report from Healthcare IT News in February 2022, citing the Union for International Cancer Control (UICC), predicted a rise in the demand for cancer chemotherapy from 10 million to 15 million by 2040. This surge in demand underscores the increasing reliance on chemotherapy, thereby driving the growth of the sarcoma drugs market.

Key players in the sarcoma drugs market are prioritizing the development of innovative oral medications to improve patient adherence and treatment outcomes. Oral medications are those administered by mouth in forms such as tablets, capsules, or liquid solutions. They are absorbed through the digestive system, offering a convenient and non-invasive way to deliver treatment. For example, in April 2024, Novugen Pharma LLC, a pharmaceutical company based in the U.S., introduced 200 mg pazopanib tablets as a generic alternative to Votrient. This product, which has been approved by the US FDA for the treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS), underscores Novugen's expertise in complex anticancer formulations. Its launch is expected to improve patient access to effective therapies, significantly influencing the sarcoma drug market by enhancing competition in a previously limited landscape.

Major companies in the sarcoma drugs market are strategically focusing on obtaining product approvals to drive market revenues. Genentech Inc., a US-based biotechnology company, received FDA approval in December 2022 for tecentriq (atezolizumab), a monoclonal antibody. Tecentriq is indicated for the treatment of adult patients with advanced alveolar soft part sarcoma (ASPS), marking the first-ever approved treatment for this uncommon soft tissue sarcoma. The medication targets the PD-1/PD-L1 pathway, blocking immune system suppression and offering a promising therapeutic option for individuals diagnosed with ASPS.

In March 2023, Pfizer Inc., a prominent US-based pharmaceutical company, completed the acquisition of Seagen Inc. for $43 billion. This strategic move positions Pfizer Inc. as a leader in cancer care and doubles the size of its oncology portfolio. Seagen Inc., a biotechnology company, is known for its focus on developing new cancer therapies. The acquisition underscores Pfizer's commitment to advancing its capabilities in the oncology space through strategic partnerships and expansion of its product offerings.

Major companies operating in the sarcoma drugs market include Amgen Inc., Bayer AG, Eisai Co. Ltd., Eli Lilly and Company, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc., AgonOX Inc., Daiichi Sankyo Company Limited, Merck & Co. Inc., AbbVie Inc., Amneal Pharmaceuticals LLC, Pharma Mar SA, Bristol-Myers Squibb Company, Fresenius Kabi AG, Ipsen SA, Radiopharm Theranostics, Akeso Biopharma, AstraZeneca plc, BeiGene Ltd., Bausch Health Companies Inc., Shenzhen Chipscreen Biosciences Co. Ltd., Teva Pharmaceuticals Industries Ltd., Monopar Therapeutics Inc., Incyte Corporation, Sanofi SA, Takeda Pharmaceutical Company Limited, Roche Holding AG

North America was the largest region in the sarcoma drugs market in 2024. The regions covered in the sarcoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the sarcoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The sarcoma drug market consists of sales of atezolizumab, cosmegen, dactinomycin, doxorubicin hydrochloride, eribulin mesylate, fyarro, and gleevec. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sarcoma Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sarcoma drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sarcoma drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sarcoma drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Chemotherapy; Targeted Therapy
• 2) By Disease Indication: Malignant Bone Tumors; Soft Tissue Sarcomaz
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Chemotherapy: Anthracyclines; Alkylating Agents; Antimetabolites; Other Chemotherapeutic Agents
• 2) By Targeted Therapy: Tyrosine Kinase Inhibitors; MTOR Inhibitors; Monoclonal Antibodies; Other Targeted Therapies
• Companies Mentioned: Amgen Inc.; Bayer AG; Eisai Co. Ltd.; Eli Lilly and Company; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Sarcoma Drugs Market Characteristics

3. Sarcoma Drugs Market Trends And Strategies

4. Sarcoma Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Sarcoma Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Sarcoma Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Sarcoma Drugs Market Growth Rate Analysis
• 5.4. Global Sarcoma Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Sarcoma Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Sarcoma Drugs Total Addressable Market (TAM)

6. Sarcoma Drugs Market Segmentation

• 6.1. Global Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• 6.2. Global Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Malignant Bone Tumors
• Soft Tissue Sarcomas
• 6.3. Global Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.4. Global Sarcoma Drugs Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anthracyclines
• Alkylating Agents
• Antimetabolites
• Other Chemotherapeutic Agents
• 6.5. Global Sarcoma Drugs Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors
• MTOR Inhibitors
• Monoclonal Antibodies
• Other Targeted Therapies

7. Sarcoma Drugs Market Regional And Country Analysis

• 7.1. Global Sarcoma Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Sarcoma Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Sarcoma Drugs Market

• 8.1. Asia-Pacific Sarcoma Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Sarcoma Drugs Market

• 9.1. China Sarcoma Drugs Market Overview
• 9.2. China Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Sarcoma Drugs Market

• 10.1. India Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Sarcoma Drugs Market

• 11.1. Japan Sarcoma Drugs Market Overview
• 11.2. Japan Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Sarcoma Drugs Market

• 12.1. Australia Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Sarcoma Drugs Market

• 13.1. Indonesia Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Sarcoma Drugs Market

• 14.1. South Korea Sarcoma Drugs Market Overview
• 14.2. South Korea Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Sarcoma Drugs Market

• 15.1. Western Europe Sarcoma Drugs Market Overview
• 15.2. Western Europe Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Sarcoma Drugs Market

• 16.1. UK Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Sarcoma Drugs Market

• 17.1. Germany Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Sarcoma Drugs Market

• 18.1. France Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Sarcoma Drugs Market

• 19.1. Italy Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Sarcoma Drugs Market

• 20.1. Spain Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Sarcoma Drugs Market

• 21.1. Eastern Europe Sarcoma Drugs Market Overview
• 21.2. Eastern Europe Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Sarcoma Drugs Market

• 22.1. Russia Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Sarcoma Drugs Market

• 23.1. North America Sarcoma Drugs Market Overview
• 23.2. North America Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Sarcoma Drugs Market

• 24.1. USA Sarcoma Drugs Market Overview
• 24.2. USA Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Sarcoma Drugs Market

• 25.1. Canada Sarcoma Drugs Market Overview
• 25.2. Canada Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Sarcoma Drugs Market

• 26.1. South America Sarcoma Drugs Market Overview
• 26.2. South America Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Sarcoma Drugs Market

• 27.1. Brazil Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Sarcoma Drugs Market

• 28.1. Middle East Sarcoma Drugs Market Overview
• 28.2. Middle East Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Sarcoma Drugs Market

• 29.1. Africa Sarcoma Drugs Market Overview
• 29.2. Africa Sarcoma Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Sarcoma Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Sarcoma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Sarcoma Drugs Market Competitive Landscape And Company Profiles

• 30.1. Sarcoma Drugs Market Competitive Landscape
• 30.2. Sarcoma Drugs Market Company Profiles
  • 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Sarcoma Drugs Market Other Major And Innovative Companies

• 31.1. F. Hoffmann-La Roche Ltd.
• 31.2. Johnson & Johnson Services Inc.
• 31.3. Novartis AG
• 31.4. Pfizer Inc.
• 31.5. AgonOX Inc.
• 31.6. Daiichi Sankyo Company Limited
• 31.7. Merck & Co. Inc.
• 31.8. AbbVie Inc.
• 31.9. Amneal Pharmaceuticals LLC
• 31.10. Pharma Mar SA
• 31.11. Bristol-Myers Squibb Company
• 31.12. Fresenius Kabi AG
• 31.13. Ipsen SA
• 31.14. Radiopharm Theranostics
• 31.15. Akeso Biopharma

32. Global Sarcoma Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sarcoma Drugs Market

34. Recent Developments In The Sarcoma Drugs Market

35. Sarcoma Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Sarcoma Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Sarcoma Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Sarcoma Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer